Recent News
Orphagen Pharmaceuticals and the Pharmaceutical Division of Japan Tobacco Enter into a Collaborative Agreement
San Diego, June 1, 2018 – Orphagen Pharmaceuticals, a privately held pharmaceutical company, announced today that it has entered into a collaborative agreement with the pharmaceutical division of Japan Tobacco Inc. (JT) to discover, develop and commercialize drugs...
Orphagen Pharmaceuticals Awarded Additional US Patent for Modulators of Orphan Nuclear Receptor ROR-gamma
San Diego, June 1, 2018 – Orphagen Pharmaceuticals, a privately held pharmaceutical company, announced today that it has been awarded US patent 9,657,053 for the use of small molecule ligands to inhibit retinoid-related orphan receptor gamma...
ORPHAGEN PARTNER, JAPAN TOBACCO, INITIATES A PHASE I CLINICAL TRIAL OF A NOVEL SMALL MOLECULE THERAPEUTIC FOR AUTOIMMUNE AND ALLERGIC DISEASES
Orphagen Pharmaceuticals, Inc., a privately held company, announced today that its partner, Japan Tobacco Inc. (“JT”), has entered Phase I clinical trials with an oral small molecule, JTE-451, for treatment of autoimmune and allergic diseases. This is a major...
Orphagen Pharmaceuticals Presents Pharmacology of ROR-beta Antagonists at the Keystone Symposium on Nuclear Receptors
Orphagen Pharmaceuticals, a privately-held emerging pharmaceutical company, described for the first time properties of small molecule antagonists to ROR-beta, an orphan nuclear receptor, at the Keystone Symposium on Nuclear Receptors taking place January 10-14 at...
Orphagen Pharmaceuticals Awarded Federal Funding to Investigate a Novel Drug Discovery Target for Sickle Cell Disease
Orphagen Pharmaceuticals, a privately-held pharmaceutical company, announced today that the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health has awarded the company a highly competitive Phase 1 Small Business Innovative Research...